Compare Fresenius Kabi Onco. with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs AUROBINDO PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. AUROBINDO PHARMA FRESENIUS KABI ONCO./
AUROBINDO PHARMA
 
P/E (TTM) x 22.1 19.8 111.9% View Chart
P/BV x 3.1 4.3 72.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 FRESENIUS KABI ONCO.   AUROBINDO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
AUROBINDO PHARMA
Mar-19
FRESENIUS KABI ONCO./
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs176830 21.2%   
Low Rs79527 14.9%   
Sales per share (Unadj.) Rs37.7333.9 11.3%  
Earnings per share (Unadj.) Rs5.140.4 12.6%  
Cash flow per share (Unadj.) Rs6.751.8 13.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs42.5237.1 17.9%  
Shares outstanding (eoy) m158.23585.91 27.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.0 166.2%   
Avg P/E ratio x25.016.8 148.6%  
P/CF ratio (eoy) x18.913.1 144.4%  
Price / Book Value ratio x3.02.9 104.5%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m20,135397,569 5.1%   
No. of employees `0001.217.9 6.5%   
Total wages/salary Rs m70325,849 2.7%   
Avg. sales/employee Rs Th5,176.210,956.9 47.2%   
Avg. wages/employee Rs Th610.41,447.7 42.2%   
Avg. net profit/employee Rs Th699.61,324.3 52.8%   
INCOME DATA
Net Sales Rs m5,963195,636 3.0%  
Other income Rs m181,553 1.2%   
Total revenues Rs m5,981197,189 3.0%   
Gross profit Rs m1,43039,519 3.6%  
Depreciation Rs m2586,680 3.9%   
Interest Rs m-262,626 -1.0%   
Profit before tax Rs m1,21631,767 3.8%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-881 7.7%   
Tax Rs m3427,269 4.7%   
Profit after tax Rs m80623,645 3.4%  
Gross profit margin %24.020.2 118.7%  
Effective tax rate %28.122.9 123.0%   
Net profit margin %13.512.1 111.8%  
BALANCE SHEET DATA
Current assets Rs m5,102153,645 3.3%   
Current liabilities Rs m2,385120,429 2.0%   
Net working cap to sales %45.617.0 268.3%  
Current ratio x2.11.3 167.6%  
Inventory Days Days150135 111.0%  
Debtors Days Days11364 177.9%  
Net fixed assets Rs m5,148103,909 5.0%   
Share capital Rs m158586 27.0%   
"Free" reserves Rs m6,556138,322 4.7%   
Net worth Rs m6,732138,908 4.8%   
Long term debt Rs m9521,800 52.9%   
Total assets Rs m10,388264,544 3.9%  
Interest coverage x-45.813.1 -349.5%   
Debt to equity ratio x0.10 1,091.9%  
Sales to assets ratio x0.60.7 77.6%   
Return on assets %7.59.9 75.6%  
Return on equity %12.017.0 70.3%  
Return on capital %14.623.8 61.3%  
Exports to sales %74.549.6 150.1%   
Imports to sales %24.818.8 131.9%   
Exports (fob) Rs m4,44197,091 4.6%   
Imports (cif) Rs m1,47736,741 4.0%   
Fx inflow Rs m5,29897,316 5.4%   
Fx outflow Rs m1,77240,589 4.4%   
Net fx Rs m3,52556,727 6.2%   
CASH FLOW
From Operations Rs m1,27416,220 7.9%  
From Investments Rs m-1,204-28,768 4.2%  
From Financial Activity Rs m-19619,191 -1.0%  
Net Cashflow Rs m-1266,656 -1.9%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 9.6 27.7 34.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   42,599 69,601 61.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   FDC  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - VENUS REMEDIES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS